TI
EDIT icon

tru Independence’s Editas Medicine EDIT Stock Holding History

tru Independence’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-111
Closed -$7.78K – 411
2020
Q4 		$7.78K Buy
+111
New +$4.56K 0.01% 267
2020
Q3 		– Sell
-910
Closed -$26 – 475
2020
Q2 		$26 Buy
+910
New +$23.8K ﹤0.01% 466

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

tru Independence's EDIT Position: Q1 2021 in Review

tru Independence sold out of Editas Medicine (EDIT) in Q1 2021, closing a stake of 111 shares — an estimated $7.78K sold.

tru Independence first reported a position in EDIT in Q2 2020 and held it in 2 quarters. The position peaked at $7.78K in Q4 2020. 312 funds tracked by Wall St. Rank hold EDIT as of Q1 2021.

  • tru Independence reported no remaining Editas Medicine position as of Q1 2021 after selling out during the quarter.
  • tru Independence sold 111 Editas Medicine shares in Q1 2021, an estimated $7.78K.
  • tru Independence first reported a position in Editas Medicine in Q2 2020 and held it in 2 quarters.
  • tru Independence's Editas Medicine position peaked at $7.78K in Q4 2020.
  • 312 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2021.

Based on tru Independence's 13F filing for Q1 2021, filed 20 May 2021.